About

Terremoto is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease.

Our Mission

Delivering Medicines with Superior Therapeutic Benefit for Patients

We develop groundbreaking, best-in-class precision therapies to meet urgent patient needs. Through relentless science and deep purpose, we bring life-changing hope to those who need it most.

Enter covalent chemistry.

At Terremoto, we are breaking open the covalent drug universe with the power of lysine-targeted chemistry. In harnessing lysine-based covalency across the disease spectrum, we are focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Our founders helped create this emergent area of science, enabling our team of world-class chemists, biologists and drug developers to pursue a well-defined platform approach and translate treatments to patients as quickly as possible.

We view ourselves as champions for patients. The ultimate driving force behind our work is bringing highly effective medicines to people with devastating diseases as quickly as we possibly can.

The Earth-Shakers

Founded by the Pioneers

With a leadership team and advisory board bringing hundreds of collective years of experience in drug discovery, development, and global regulatory approval, we have the expertise to turn our ambitious vision into life-changing therapies.

James Christensen, Ph.D.

President, Head of Research & Development

Ronald Shazer, M.D., MBA

Senior Vice President, Head of Clinical Development

Paul Stephensen

Vice President, Finance

Maika Adair

Director, Clinical Supply Chain, Technical Operations

Noleen Bonfante

Executive Director, Clinical Operations

Curtis Chin, M.D., Ph.D.

Executive Medical Director

Hamlet Chu, Ph.D.

Senior Director, Business Development

Matthew Condakes, Ph.D.

Director, Medicinal Chemistry

Michael Corbett, Ph.D.

Senior Director, Head of Technical Operations

Janaina Dargell

Director, Human Resources

Subhamoy Das, Ph.D.

Principal Scientist, Biology

Mark Eskes

Senior Director, Project Management, Technical Operations

George Gindoyan

Executive Director, Information Technology and Informatics

Renee Himes

Associate Director, Clinical Operations

Nikhil Loka, Ph.D.

Director, Drug Product Development, Technical Operations

Romel Montellano, MBA

Executive Director, Regulatory Operations

Johnson Nguyen

Senior Manager, Accounting Operations

Sarah Schisla

Senior Associate Scientist, Technical Operations

Terri Schoeneman

Executive Director, Quality Assurance

Jane Shank

Business Manager/Senior Executive Assistant

Wagner Silva

Associate Director, Clinical Operations

Nicola Stagg, Ph.D., DABT

Executive Director, Head of Toxicology

Jessica Sun, Ph.D.

Executive Director, Head of In Vivo Pharmacology

Adam Zajdlik

Senior Scientist, Medicinal Chemistry

Board of Directors

Charles Baum, M.D., Ph.D.

CEO, Terremoto

James Christensen, Ph.D.

President, Head of Research & Development, Terremoto

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Daniel O’Connell, M.D., Ph.D.

Partner, Novo Holdings Venture Investments

Charles Baum, M.D., Ph.D.

Chief Executive Officer

Peter Thompson, M.D.

Co-founder and Board Chairman, Terremoto
General Partner, OrbiMed

Founders

Scientific Advisors

Peter Thompson, M.D.

Co-founder and Board Chairman, Terremoto
General Partner, OrbiMed

Reid Huber, Ph.D.

Partner, Third Rock Ventures

Kevin Koch, Ph.D.

President, CEO and CFO, Edgewise
Venture Partner, OrbiMed

Jack Taunton, Ph.D.

Co-founder, Terremoto
Professor, Cellular Molecular
Pharmacology, UCSF

Matthew Jacobson, Ph.D.

Co-founder, Terremoto
Professor, Dept. of Pharmaceutical Chemistry, UCSF

John Link, Ph.D.

Former Vice President, Medicinal Chemistry, Gilead Sciences

Investors

 
© 2026 Terremoto Biosciences